ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients with Major Depressive Disorder Who were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Phase 3
Recruiting
- Conditions
- Major Depressive Disorder
- Registration Number
- JPRN-jRCT2080221483
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients must have completed previous Study
adult male or female outpatients at least 18 years of age or older at the time of informed consent
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method